ReviewBiology of reproduction2020
Retinoic acid receptor antagonists for male contraception: current status†.
Review in Biology of reproduction, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- A systematic review of retinoic acid in the journey of spermatogonium to spermatozoa: From basic to clinical application.F1000Research · 2022Pooled it
- Novel male contraceptives.Future science OA · 2026Review
- Retinoic Acid Signaling in Male Reproductive Biology: From Germ Cell Regulation to Contraceptive Innovation Within a One Health Framework.Animals : an open access journal from MDPI · 2026Review
- Development of a Second-Generation RARα Selective Antagonist as an Orally Bioavailable, Effective, Safe, and Reversible Male Contraceptive.Journal of medicinal chemistry · 2026Article
- Meiotic prophase I disruption as a strategy for nonhormonal male contraception using small-molecule inhibitor JQ1.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- From Discovery to Clinical Trial: YCT-529, an Oral NonHormonal Male Contraceptive Targeting the Retinoic Acid Receptor Alpha.Journal of medicinal chemistry · 2026Article
- Differential retinoic acid responses across testicular developmentbioRxiv : the preprint server for biology · 2025Article
- Article
- In vitro models of the male reproductive system: applications for developmental and reproductive toxicology.Toxicological sciences : an official journal of the Society of Toxicology · 2025Review
- Effect of Retinoic Acid on the Cerebral Vasculature: Analysis of the Vasoactive Response of Smooth Muscle Cells in Normal and Ischemic Contexts.Journal of xenobiotics · 2025Article
- Targeting the retinoid signaling pathway with YCT-529 for effective and reversible oral contraception in mice and primates.Communications medicine · 2025Article
- Novel Genes of the Male Reproductive System: Potential Roles in Male Reproduction and as Non-hormonal Male Contraceptive Targets.Molecular reproduction and development · 2024Review
- Emerging approaches to male contraception.Andrology · 2024Review
- The uniqueness of on-demand male contraception.Molecular aspects of medicine · 2024Review
- Targeting nuclear receptor corepressors for reversible male contraception.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Frequency, morbidity and equity - the case for increased research on male fertility.Nature reviews. Urology · 2024Review
- Chaperone-mediated autophagy as a modulator of aging and longevity.Frontiers in aging · 2024Review
- Nonhormonal Male Contraceptive Development-Strategies for Progress.Pharmacological reviews · 2023Review
- Strategies for developing retinoic acid receptor alpha-selective antagonists as novel agents for male contraception.European journal of medicinal chemistry · 2023Article
- Male contraception: narrative review of ongoing research.Basic and clinical andrology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Retinoic acid receptor alpha (RARA), a nuclear receptor protein, has been validated as a target for male contraception by gene knockout studies and also pharmacologically using a pan-retinoic acid receptor antagonist. Retinoic acid receptor alpha activity is indispensable for the spermatogenic process, and therefore its antagonists have potential as male contraceptive agents. This review discusses the effects of systematic dosing regimen modifications of the orally bioavailable and reversible pan-antagonist BMS-189453 as well as studies with the alpha-selective antagonists BMS-189532 and BMS-189614 in a murine model. We also provide an overview of structure-activity studies of retinoic acid receptor alpha antagonists that provide insight for the design of novel alpha-selective ligands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.